Verrica Pharmaceuticals Inc. (VRCA)

Verrica Pharmaceuticals' stock price increased by 127.64% over the past six months. The company reported its Fourth Quarter and Full Year 2025 financial results, highlighting record revenue growth. YCANTH was launched in Japan by Torii Pharmaceutical. Zacks upgraded Verrica Pharmaceuticals to a "Strong Buy" rating. The company announced the acceptance of a late-breaking abstract highlighting the potential abscopal effect of VP-315. Verrica announced an upcoming presentation of Phase 2 data for VP-315, which led to a 12.58% increase in the stock price. Verrica is scheduled to report its first-quarter 2026 financial results and provide a corporate update on May 12, 2026.

Specific detailed information on demand seasonality for Verrica Pharmaceuticals' products is limited. Seasonal chart analysis suggests a "Buy Date" of December 19 and a "Sell Date" of April 6, which has historically resulted in an average return of 12.64% above the S&P 500 Total Return Index. The seasonal timeframe for VRCA correlates poorly with the seasonal strength of the broader Healthcare sector.

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company focused on developing and commercializing treatments for skin diseases. Their product portfolio includes YCANTH (VP-102) for molluscum, VP-103 for plantar warts, and VP-315 for dermatology oncologic conditions.

Verrica Pharmaceuticals is headquartered in West Chester, Pennsylvania, and primarily conducts clinical trials in the United States. They have a collaboration with Torii Pharmaceutical Co., Ltd. for development and commercialization in Japan, where YCANTH has launched.

Verrica Pharmaceuticals has received a consensus rating of "Reduce" from brokerages, with an average rating score of 1.75. The average twelve-month target price among brokerages is $17.00. The Rosen Law Firm and The Schall Law Firm announced investigations into breaches of fiduciary duties by the directors and officers of Verrica Pharmaceuticals Inc. The company reported a Q1 EPS of ($0.51), missing analysts' consensus estimates of ($0.43) by $0.08.

Verrica Pharmaceuticals Inc. is owned by a mix of institutional shareholders, individual insiders, and retail investors. Institutions hold 30.25% of the stock, with Armistice Capital, Llc, and Caligan Partners LP among the largest institutional shareholders. Insiders own a significant portion of the company, with Paul B. Manning being the largest individual shareholder. Retail investors hold 0.00% of the company's stock.